Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | CA7 | P43166 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.46 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5770092 | 0.83 | PLK1 (0.45) | LMNATSHRKDM4ESLC6A4SLC6A3 | |
| SCHEMBL70429 | 0.82 | LMNA (0.59) | LMNATSHRKDM4ECA1CA2 | |
| SCHEMBL9300933 | 0.81 | LMNA (0.66) | LMNATSHRKDM4ECA1CA2 | |
| SCHEMBL16661164 | 0.81 | TSHR (0.66) | LMNATSHRKDM4ECA1CA2 | |
| SCHEMBL2748162 | 0.80 | NR4A1 (0.50) | TSHRKDM4ECA1CA2CA9 | |
| SCHEMBL7214394 | 0.78 | ERN1 (0.54) | LMNATSHRKDM4ECA1CA2 | |
| SCHEMBL12125211 | 0.78 | TSHR (0.49) | LMNATSHRKDM4ECA1CA2 | |
| SCHEMBL5740332 | 0.78 | NR4A1 (0.48) | TSHRKDM4ECA1CA2CA9 | |
| SCHEMBL2174563 | 0.78 | KDM4E (0.61) | LMNATSHRKDM4ECA1CA2 | |
| SCHEMBL12345028 | 0.78 | LMNA (0.50) | LMNATSHRKDM4ECA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3112351-B1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2022-03-30 | — | — | EP | disclosed |
| US-9914707-B2 | Naphthylamide compound, preparation method and use thereof | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2018-03-13 | — | — | US | disclosed |
| EP-2488506-B1 | FLUORESCENT CALCIUM INDICATORS THAT ARE RATIOMETRIC AND EMIT IN THE RED SPECTRUM | ASANTE RES LLC (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20170066723-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2017-03-09 | — | — | US | disclosed |
| EP-3112351-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | Shanghai Institute Of Materia Medica Chinese Academy of Sciences (CN) | 2017-01-04 | — | — | EP | disclosed |
| CN-102770417-A | Fluorescent calcium indicators that are ratiometric and emit in the red spectrum | ASANTE RES LLC | 2012-11-07 | — | — | CN | disclosed |
| US-8178557-B2 | Compounds and methods of use | AMGEN INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110257399-A1 | Fluorescent calcium indicators that are ratiometric and emit in the red spectrum | MINTA AKWASI | 2011-10-20 | — | — | US | disclosed |
| US-20090176774-A1 | Compounds and methods of use | AMGEN INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7435823-B2 | Compounds and methods of use | AMGEN INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20060241115-A1 | Compounds and methods of use | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1713484-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005070891-A2 | COMPOUNDS AND METHODS OF USE | AMGEN INC (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241115-A1 | Compounds and methods of use | HGF, HGFAC, MET | LMNA 3258/4885TSHR 3003/4885KDM4E 4131/4885 |
| US-20110257399-A1 | Fluorescent calcium indicators that are ratiometric and emit in the red spectrum | SARAF, CA2, ORAI1 | LMNA 167/4885TSHR 4103/4885KDM4E 2869/4885 |
| US-20090176774-A1 | Compounds and methods of use | HGF, HGFAC, MET | LMNA 3258/4885TSHR 3003/4885KDM4E 4131/4885 |
| US-20170066723-A1 | NAPHTHYLAMIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | KDR, FLT1, FLT4 | LMNA 704/4885TSHR 4014/4885KDM4E 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.